HER2+ Breast Cancer

Real-world tucatinib-based regimens were effective in different lines for HER2-positive metastatic breast cancer, including after trastuzumab deruxtecan.

Dalpiciclib plus pyrotinib and endocrine therapy was active with a manageable safety profile in patients with ER-positive, HER2-positive advanced breast cancer.

Jessica Paulus, ScD, discusses the clinical implications of using real-world data to add an external control arm to a phase 2 study in HER2+ breast cancer.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

BB-1701 generated responses with manageable safety in HER2-expressing breast cancer previously treated with an ADC with a topoisomerase I inhibitor.

The novel bispecific antibody TQB2930 plus chemotherapy elicited responses in heavily pretreated HER2-positive breast cancer.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.

JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.

Erika P. Hamilton, MD, highlights the unmet needs regarding treatment for brain metastases in HER2-positive metastatic breast cancer.

The FDA granted breakthrough therapy designation to first-line trastuzumab deruxtecan plus pertuzumab in HER2-positive metastatic breast cancer.

Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.

Heather McArthur, MD, discusses monitoring strategies for interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Jessica Paulus, ScD, discusses using real-world data to add an external control arm to a study of tucatinib plus liposomal doxorubicin in HER2+ breast cancer.

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

HER2DX genomic scoring predicted pCR after neoadjuvant THP in a high-risk subgroup of patients with HER2-positive early breast cancer.

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Gedatolisib generated clinical activity in metastatic castration-resistant prostate cancer and HER2-positive breast cancer.

Treatment with KN026 plus KN046 demonstrated durable responses and a manageable safety profile in previously treated HER2-positive breast cancer.

IBI354 continued to demonstrate tolerability and was active in pretreated, HER2-positive advanced breast cancer.

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

The bispecific antibody-drug conjugate TQB2102 was safe and active in pretreated, recurrent or metastatic, HER2-positive breast cancer.

As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.

T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.